HSA
TARS icon

Hussman Strategic Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Hussman Strategic Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
21,000
+4,200
+25% +$268K 0.3% 154
2026
Q1 		$1.18M Hold
16,800
– – 0.25% 179
2025
Q4 		$1.38M Sell
16,800
-14,700
-47% -$1.1M 0.33% 136
2025
Q3 		$1.87M Buy
+31,500
New +$1.55M 0.41% 113

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Hussman Strategic Advisors's TARS Position: Q2 2026 in Review

Hussman Strategic Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 25% in Q2 2026, buying an estimated $268K and bringing the position to 21,000 shares worth $1.32M. The position accounts for 0.3% of the portfolio, ranked #154.

Hussman Strategic Advisors first reported a position in TARS in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.87M in Q3 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Hussman Strategic Advisors held 21,000 shares of Tarsus Pharmaceuticals worth $1.32M as of Q2 2026.
  • Hussman Strategic Advisors bought 4,200 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $268K.
  • Tarsus Pharmaceuticals made up 0.3% of Hussman Strategic Advisors's portfolio in Q2 2026, its #154 holding.
  • Hussman Strategic Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Hussman Strategic Advisors's Tarsus Pharmaceuticals position peaked at $1.87M in Q3 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.